Close

November 21, 2023

VivArt-X receives pre-seed funding for accelerating and developing a proof-of-concept

VivArt-X has successfully closed a pre-seed investment round of 660,000 euros, thanks to the support of Brabant Startup Fund, the Brabantse Ontwikkelings Maatschappij (BOM), TU/e Participation Holding (the Gate), and a group of informal investors. Obtaining this funding will allow them to advance their lead program to pre-clinical development, a significant step toward enhancing regenerative applications.

You can read more about this here.